Axsome Therapeutics
AXSM
$217.99
-7.10%
Axsome Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders with limited treatment options. It is a niche player in CNS drug development, with a pipeline including AXS-05, AXS-07, AXS-12, and AXS-14, targeting conditions like major depressive disorder and narcolepsy. The current investor narrative centers on the company's rapid revenue growth from its commercialized products and the potential for pipeline catalysts, though ongoing net losses and high debt levels fuel debate about its path to profitability.…
AXSM
Axsome Therapeutics
$217.99
Related headlines
Investment Opinion: Should I buy AXSM Today?
Rating: Hold. Axsome is a high-growth biotech with strong revenue momentum and a promising pipeline, but its unprofitability, high debt, and elevated valuation warrant caution. The consensus Strong Buy rating and average target of $282.51 suggest upside, but the risk/reward is balanced.
Supporting Evidence: Revenue grew 57.4% YoY to $191.2 million, with gross margins of 92.3%. The trailing PS ratio of 14.2x is high but supported by growth, and the PEG ratio of 1.29 suggests reasonable valuation relative to earnings growth. However, the company remains unprofitable with negative free cash flow and a debt-to-equity ratio of 2.73. The analyst average target implies 17.2% upside, but the low target of $242 offers minimal upside.
Risks & Conditions: The biggest risks are failure to achieve profitability, revenue deceleration, and multiple compression. This Hold would upgrade to Buy if the company reports positive free cash flow or if the PS ratio compresses below 10x. It would downgrade to Sell if revenue growth falls below 20% YoY or if debt levels increase further. Overall, the stock appears fairly valued relative to its growth rate but overvalued on an absolute basis, given the lack of profitability.
Sign up to view all
AXSM 12-Month Price Forecast
Axsome's outlook is balanced. The company has strong revenue growth and high gross margins, but unprofitability and high debt create risk. The base case of 40-50% growth and gradual margin improvement is most likely, supporting the stock near current levels. A bullish scenario requires faster-than-expected profitability, while a bearish scenario could emerge from growth deceleration or pipeline failures. The neutral stance reflects the balanced risk/reward, with a slight tilt toward upside given analyst support.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Axsome Therapeutics's 12-month outlook, with a consensus price target around $282.51 and implied upside of +29.6% versus the current price.
Average Target
$282.51
0 analysts
Implied Upside
+29.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$242 - $380
Analyst target range
Axsome is covered by 21 analysts, with a consensus recommendation of Strong Buy (mean rating 1.24 on a 1-5 scale). The average target price is $282.51, implying approximately 17.2% upside from the current price of $241. The distribution leans heavily bullish, with no sell ratings and only one hold (Morgan Stanley's Equal Weight). The consensus reflects optimism about the company's growth trajectory and pipeline. The target range spans from $242 (low) to $380 (high), indicating a wide spread of 57% from low to high. The high target of $380 assumes significant multiple expansion and successful pipeline execution, while the low target of $242 suggests only modest upside and potential risks. Recent ratings from firms like HC Wainwright, RBC Capital, and TD Cowen have been consistently positive, with no downgrades in the past few months. The wide target range signals high uncertainty, but the strong buy consensus and recent upgrades point to a favorable outlook among analysts.
Bulls vs Bears: AXSM Investment Factors
Axsome presents a compelling growth story with rapid revenue expansion, high gross margins, and strong analyst support. However, the company remains unprofitable with negative free cash flow, high debt, and an elevated valuation that leaves little room for error. The bull case hinges on sustained revenue growth and a path to profitability, while the bear case centers on financial risk and potential multiple compression. The single most important tension is whether the company can achieve profitability before growth decelerates, as the current valuation already prices in significant future success.
Bullish
- Rapid Revenue Growth: Revenue grew 57.4% year-over-year to $191.2 million in Q1 2026, driven by product sales of $189.4 million. This strong top-line momentum supports the thesis of a successful transition from clinical to commercial stage.
- High Gross Margin: Gross margin is 92.3% in Q1 2026, typical for biotech with low cost of goods sold. This indicates strong pricing power and scalability as revenue grows.
- Strong Analyst Consensus: 21 analysts rate the stock a Strong Buy with a mean rating of 1.24 and average target of $282.51, implying 17.2% upside. No sell ratings and only one hold suggest broad optimism.
- Narrowing Net Losses: Net loss improved from -$74.9 million in Q4 2024 to -$64.5 million in Q1 2026, demonstrating progress toward profitability as revenue scales.
Bearish
- Unprofitable with Negative Free Cash Flow: Despite revenue growth, the company reported a net loss of -$64.5 million and negative free cash flow of -$20.8 million in Q1 2026. This reliance on external financing (common stock issuance of $16.2 million) raises sustainability concerns.
- High Debt-to-Equity Ratio: Debt-to-equity ratio is 2.73, indicating significant leverage. Combined with negative ROE of -207.5%, this financial risk could pressure the stock if growth decelerates.
- Elevated Valuation Multiples: Trailing PS ratio of 14.2x and PB ratio of 102.9x are extremely high. While justified by growth, any slowdown could lead to multiple compression and significant downside.
- Wide Analyst Target Range: Analyst targets range from $242 to $380, a 57% spread, indicating high uncertainty. The low target of $242 is only 0.4% above the current price, suggesting limited upside in a bear case.
AXSM Technical Analysis
Axsome is in a strong uptrend, with the stock up 129.6% over the past year and currently trading at $241, which is 92.6% of its 52-week range ($96.09 to $260.19). This positioning near the highs suggests robust momentum but also potential overextension, as the stock has rallied sharply from its 52-week low. The 1-year relative strength of 113.1% versus the S&P 500's 16.5% underscores its exceptional outperformance. Short-term momentum shows a mixed picture: the 1-month price change is +1.3%, while the 3-month change is +29.6%, indicating a deceleration from the rapid gains seen earlier in the year. The 1-month relative strength of 0.5% suggests near-term underperformance versus the market, potentially signaling a consolidation phase or profit-taking after the strong run. The 6-month change of +29.6% aligns with the 3-month figure, confirming a sustained upward trajectory. Key support lies at the 52-week low of $96.09, while resistance is at the 52-week high of $260.19. A breakout above $260.19 would signal continued bullish momentum and potentially open the door to further upside, while a breakdown below recent support near $220 could indicate a trend reversal. The stock's beta of 0.60 suggests it is less volatile than the overall market, which is unusual for a biotech and may reflect its recent commercial success and lower speculative risk.
Beta
0.60
0.60x market volatility
Max Drawdown
-18.5%
Largest decline past year
52-Week Range
$96-$260
Price range past year
Annual Return
+115.0%
Cumulative gain past year
| Period | AXSM Return | S&P 500 |
|---|---|---|
| 1m | -9.4% | +0.2% |
| 3m | +5.5% | +3.7% |
| 6m | +18.3% | +8.0% |
| 1y | +115.0% | +18.2% |
| ytd | +22.0% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AXSM Fundamental Analysis
Revenue is growing rapidly, with Q1 2026 revenue of $191.2 million, up 57.4% year-over-year from $121.5 million in Q1 2025. The sequential trend is also positive, with revenue increasing from $196.0 million in Q4 2025 to $191.2 million in Q1 2026, though there is a slight dip. Product revenue of $189.4 million in Q1 2026 is the primary driver, supplemented by royalty and milestone revenue. This growth trajectory supports the investment case for a company transitioning from clinical-stage to commercial-stage, though the pace of growth will need to be sustained to justify the current valuation. The company remains unprofitable, with a net loss of $64.5 million in Q1 2026, though this loss has narrowed from $74.9 million in Q4 2024. Gross margin is high at 92.3% in Q1 2026, typical for biotech with low cost of goods sold. However, operating margin is negative at -33.1%, reflecting heavy SG&A and R&D spending. The trajectory toward profitability is improving as revenue scales, but the company still has a negative net margin of -33.8%. Axsome has a debt-to-equity ratio of 2.73, indicating significant leverage, and free cash flow was negative $20.8 million in Q1 2026. The company's current ratio of 1.55 suggests adequate liquidity, but the negative free cash flow and high debt levels raise concerns about financial risk. ROE is deeply negative at -207.5%, reflecting the net losses relative to shareholder equity. The company relies on external financing, as evidenced by common stock issuance of $16.2 million in Q1 2026, to fund operations.
Quarterly Revenue
$191203000.0B
2026-03
Revenue YoY Growth
+57.4%
YoY Comparison
Gross Margin
92.3%
Latest Quarter
Free Cash Flow
$-70993000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AXSM Overvalued?
Since net income is negative, the price-to-sales (PS) ratio is the primary valuation metric. The trailing PS ratio is 14.2x, while the forward PS ratio is not directly provided but can be inferred from estimated revenue. The high PS ratio reflects the market's expectation of continued rapid revenue growth. The PEG ratio of 1.29 suggests the stock is reasonably priced relative to its growth rate, but this relies on earnings estimates that may be optimistic. Compared to the industry average PS ratio (data not provided), Axsome trades at a significant premium, likely justified by its high revenue growth and gross margins. The PS ratio of 14.2x is elevated for a biotech, but the company's commercial success and pipeline potential may warrant this premium. Historically, Axsome's PS ratio has ranged from around 28x in early 2023 to over 45x in Q1 2026, indicating that the current 14.2x is near the lower end of its historical range. This suggests the stock may be undervalued relative to its own history, but the decline in PS ratio could also reflect market skepticism about sustaining growth. The PB ratio of 102.9x is extremely high, typical for companies with intangible assets and negative book equity.
PE
-49.6x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-53.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Axsome's primary financial risk is its ongoing unprofitability and negative free cash flow. In Q1 2026, the company reported a net loss of $64.5 million and free cash flow of -$20.8 million, despite revenue of $191.2 million. The debt-to-equity ratio of 2.73 indicates significant leverage, and the negative ROE of -207.5% reflects the erosion of shareholder equity. The company relies on external financing, as evidenced by $16.2 million in common stock issuance in Q1 2026. If revenue growth slows or operating expenses remain high, the company may need to raise additional capital, diluting existing shareholders.
Market & Competitive Risks: The stock trades at a trailing PS ratio of 14.2x, which is elevated for a biotech company. While this premium is supported by rapid growth, any deceleration could lead to multiple compression. The beta of 0.60 suggests lower market correlation than typical biotech, but the stock is still sensitive to sector rotation and risk appetite. Recent news highlights the company's strong revenue growth and pipeline, but competitive pressures in CNS disorders could limit market share. The wide analyst target range (low $242 to high $380) underscores uncertainty about future growth and valuation.
Worst-Case Scenario: In a worst-case scenario, revenue growth decelerates due to competition or pipeline setbacks, leading to analyst downgrades and multiple compression. The stock could fall to its 52-week low of $96.09, representing a 60% decline from the current price of $241. This scenario would likely require a combination of missed earnings, negative pipeline news, and a broader market downturn. The historical max drawdown of -18.5% provides a less severe reference, but the high valuation amplifies downside risk.
FAQ
The key risks are: 1) Financial risk: high debt-to-equity of 2.73 and negative free cash flow of -$20.8 million, requiring external financing. 2) Valuation risk: PS ratio of 14.2x leaves little room for error; any growth deceleration could cause multiple compression. 3) Pipeline risk: dependence on successful clinical trials and FDA approvals for AXS-05 and other candidates. 4) Macro risk: beta of 0.60 suggests lower market correlation, but growth stocks are sensitive to interest rates and risk appetite. The most severe risk is a growth slowdown leading to a 60% decline to the 52-week low of $96.09.
The 12-month outlook is balanced. The base case (50% probability) expects revenue growth of 40-50% and a stock price in the $242-$282 range, aligning with the analyst average target of $282.51. The bull case (30% probability) sees the stock reaching $300-$380 on pipeline success and profitability, while the bear case (20% probability) could see a decline to $96-$200 if growth decelerates. The most likely scenario is the base case, assuming continued execution and no major setbacks.
Axsome trades at a trailing PS ratio of 14.2x, which is high for a biotech but within its historical range (28x to 45x over the past few years). The PEG ratio of 1.29 suggests it is reasonably priced relative to its earnings growth rate, but this relies on optimistic estimates. Compared to the industry average (not provided), the stock likely trades at a premium, justified by its high growth and gross margins. Overall, the stock appears fairly valued on a growth-adjusted basis but overvalued on an absolute basis given the lack of profitability.
Axsome offers a compelling growth story with 57.4% YoY revenue growth and a Strong Buy analyst consensus, but it remains unprofitable with negative free cash flow and high debt. The average analyst target of $282.51 implies 17.2% upside, but the low target of $242 offers minimal upside. For risk-tolerant investors with a long-term horizon, it could be a good buy if you believe revenue growth will continue and profitability is achievable. However, conservative investors may prefer to wait for a clearer path to profitability or a lower entry point.
Axsome is better suited for long-term investment given its growth stage and volatility. The stock has a beta of 0.60, lower than typical biotech, but still experiences significant price swings (52-week range of $96.09 to $260.19). The company is not yet profitable and does not pay a dividend, so it is not suitable for income investors. A minimum holding period of 3-5 years is recommended to allow the pipeline to mature and the company to achieve profitability. Short-term traders may find opportunities around earnings and pipeline catalysts, but the high valuation and uncertainty make it risky for short-term holds.